· 720 · Chinese Hepatology,,,
质疏松和骨矿盐疾病杂志,2016,9:215-227. and development of a screening Pharmacol
[24] Carey E J,Lai J C,Wang C multicenter study to define Ther,2019,49:194-201.
sarcopenia in patients with end-stage liver disease. Liver [31] Labenz C,Toenges G,Schattenberg JM,et -related
Transpl,2017,23:625-633. quality of life in patients with compensated and decompensated
[25] Ebadi M,Tandon P, Moctezuma-Velazquez C,et liver J Intern Med,2019,70:54-59.
subcutaneous adiposity associates with higher mortality in female [32] Fan H,Zhu novel frailty index improves risk prediction
patients with Hepatol,2018,69:608-616. of waitlist mortality over the model for end-stage liver disease
[26] Tachi Y,Kozuka A,Hirai T,et of myosteatosis on score ,2018,67:2059.
skeletal muscle volume loss in patients with chronic liver [33] Pang S,Ali A,Coombes JS,et an Optimal Liver
Gastroenterol Hepatol 201
混合型肝细胞-胆管癌的诊疗进展 来自淘豆网www.taodocs.com转载请标明出处.